Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2025 13:03 ET | Source: Shotsy Co.

UPDATE - Shotsy Names Eric Perakslis as Chief Science Officer to Advance Safe, Science-Backed GLP-1 Support

PORTLAND, Ore., Sept. 23, 2025 (GLOBE NEWSWIRE) -- When it comes to GLP-1 weight loss medications, including Ozempic®, Zepbound® and Wegovy®, having access is only part of the equation. Patients need...
September 23, 2025 08:45 ET | Source: Shotsy Co.

Shotsy Names Eric Perakslis as Chief Science Officer to Advance Safe, Science-Backed GLP-1 Support

PORTLAND, Ore., Sept. 23, 2025 (GLOBE NEWSWIRE) -- When it comes to GLP-1 weight loss medications, including Ozempic®, Zepbound® and Wegovy®, having access is only part of the equation. Patients need...
August 28, 2025 10:13 ET | Source: Spherix Global Insights

Despite Early Low Awareness, Physicians Forecast Swift Adoption of Novo Nordisk’s Wegovy in MASH, According to Spherix Global Insights

EXTON, PA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- The recent approval of Novo Nordisk’s Wegovy (semaglutide 2.4mg) as the second treatment for metabolic dysfunction-associated steatohepatitis (MASH)...
July 27, 2025 16:23 ET | Source: The Rosen Law Firm PA

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – HIMS

NEW YORK, July 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April...
July 01, 2025 16:44 ET | Source: WW International Inc.

WeightWatchers and Novo Nordisk Expand Collaboration to Improve Medication Access Through Trusted, Holistic Model of Care

WeightWatchers and Novo Nordisk expand collaboration to improve medication access through trusted, holistic model of care
June 17, 2025 09:04 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases

NorthStrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Diseases
May 22, 2025 08:16 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Related Sarcopenia

NorthStrive Biosciences Announces Completion of Phase I Strategic Review for EL-22 Targeting Muscle Loss Associated with GLP-1 Weight Loss Drugs and Age-Re
May 13, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22

Northstrive Biosciences Signs Binding Term Sheet with Modulant Biosciences for Exclusive Global Animal Health Licensing of EL-22
April 29, 2025 12:15 ET | Source: PMGC Holdings Inc.

RESEND - Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health
April 29, 2025 08:00 ET | Source: PMGC Holdings Inc.

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health

Northstrive Biosciences Strengthens IP Portfolio with New US Patent Filings for EL-22 and EL-32 Programs Covering Obesity and Animal Health